Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danoprevir and Mericitabine in Chronic Hepatitis C
NCT01483742Phase 2Completed
- Sponsor
- Roche
- Start
- Apr 2012
- Primary completion
- Sep 2013
- Modality
- Orthosteric Ligands
- Countries
- 7
01
Overview
Phase 2, open-label trial of danoprevir and mericitabine in hepatitis C (HCV) (2 arms), sponsored by Roche. Primary endpoints: Incidence of adverse events at 48 weeks, Area under the concentration-time curve at 24 weeks and 1 more. Started Apr 2012; status: completed.
02
Drugs
danoprevirmericitabine
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01483742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01483742.